Goro Takeda, co-founder and Managing Partner of Newton Biocapital, invests in early-stage life sciences companies (Seed. See sector focus and contact routes.
Goro Takeda, co-founder and Managing Partner of Newton Biocapital, invests in early-stage life sciences companies (Seed, Series A, Growth) in Europe and Japan that address chronic health conditions, specifically targeting oncology, metabolic, neurological, autoimmune, and genetic diseases. His firm’s distinctive thesis focuses on building a cross-border life sciences corridor between Belgium and Japan to translate scientific excellence into solutions for unmet medical needs, while providing hands-on strategic and clinical guidance beyond capital. Notable portfolio companies include SANTERO (antibiotics for drug-resistant infections), Epics Therapeutics (oncology RNA epigenetics), Synergia Medical (neurostimulation for epilepsy), and Acticor Biotech (acute thrombotic disease treatments). Specific check sizes are not publicly disclosed, though the firm manages funds totaling over €260 million (NBC I: €114M; NBC II: targeting €150M).
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Tokyo.
Investors like Goro Takeda · Full investor directory · Investor access · Company funding database